|
| Thursday, March 5, 2015 |
|
|
Eisai and Merck Enter Collaboration to Explore Novel Combination Regimens of Anti-PD-1 Therapy with Multi-targeting RTK Inhibitor and Microtubule Dynamics Inhibitor in Multiple Types of Cancer |
Eisai Co., Ltd. and Merck announced today a clinical trial collaboration to evaluate the safety, tolerability and efficacy of Merck's anti-D-1 therapy, pembrolizumab in combination with Eisai oncology compounds lenvatinib mesylate and eribulin mesylate in multiple clinical trials.
more info >> |
|
| Tuesday, March 3, 2015 |
|
|
China JSFDA Accepts Eisai's Application Seeking Additional Indication of Severe Alzheimer's Disease for Aricept |
| Eisai Co., Ltd. announced today that its New Drug Application for the additional indication of severe Alzheimer's Disease (AD) for Aricept(R) has been accepted for review by the Jiangsu Food and Drug Administration in China. more info >> |
|
| Monday, March 2, 2015 |
|
|
Eisai Launches Anticancer Agent Lenvima in the United States |
| Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has launched its in-house developed novel anticancer agent Lenvima (lenvatinib mesylate) as a treatment for locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer in the United States on February 26, 2015. more info >> |
|
| Wednesday, February 25, 2015 |
|
|
Eisai to Establish Oral Solid Dose Production Facility at New Suzhou Plant in China |
| Eisai Co., Ltd. announced today that its Chinese subsidiary, Eisai China Inc. (ECI) has decided to build a new oral solid dose (OSD) production facility at the site of its new Suzhou plant ("New Plant") located within the Suzhou Industrial Park in order to relocate and expand its existing OSD production facility ("Old Plant") within the same industrial park. more info >> |
|
|
Eisai Announces Phase III Trial of Anticancer Agent Halaven in Soft Tissue Sarcoma Shows Overall Survival Benefit in Primary Endpoint |
| Eisai Co., Ltd. announced today that in a Phase III clinical trial (Study 309) of its in-house discovered and developed anticancer agent eribulin mesylate in patients with soft tissue sarcomas, eribulin demonstrated a statistically significant extension in overall survival (OS) over the comparator treatment dacarbazine, and the study met its primary endpoint. more info >> |
|
| Tuesday, February 24, 2015 |
|
|
Additional Exploratory Analysis of Phase II Trial Suggests Anticancer Agent Lenvatinib Extends Overall Survival in Patients with Advanced Non-small Cell Lung Cancer |
| Eisai Co., Ltd. announced today the latest results of an additional exploratory analysis of a Phase II clinical trial (Study 703) of its in-house developed anticancer agent lenvatinib mesylate (Lenvima(TM)) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who had failed at least two systemic anticancer regimens. more info >> |
|
| Thursday, February 19, 2015 |
|
|
Eisai Receives Approval in Japan for Fine Granule Formulation of Anti-Arrhythmic Agent Tambocor Suitable for Pediatric Patients |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has received marketing and manufacturing approval in Japan for Tambocor Fine Granules 10%, a new formulation of anti-arrhythmic agent Tambocor (flecainide acetate). more info >> |
|
| Wednesday, July 13, 2011 |
|
|
Eisai Enters into Comprehensive Chinese Marketing Agreement Concerning Breast Cancer and Parkinson's Disease Treatments |
| Eisai Co., Ltd. announced today that it has entered into a comprehensive marketing agreement with Orion Corporation (Espoo, Finland) concerning Orion's breast cancer drug Fareston(R) (toremifene citrate) and its Parkinson's disease treatment Eldepryl(R)(selegiline hydrochloride). more info >> |
|
| Thursday, November 18, 2010 |
|
|
Eisai to Provide Medecine to Help WHO Combat Lymphatic Filariasis Epidemic |
| Eisai Co., Ltd. announced today that it has signed a statement of intent with the World Health Organization (WHO) to supply free of charge of a primary medicine for the treatment of lymphatic filariasis. more info >> |
|
| Tuesday, September 7, 2010 |
|
|
SymBio and Eisai to Launch Symbenda(R) in Singapore for the Treatment of Low-grade Non-Hodgkin's Lymphoma and Chronic Lymphatic Leukemia |
| SymBio Pharmaceuticals Limited and Eisai Co., Ltd. announced today that Eisai's Singapore subsidiary Eisai (Singapore) Pte. Ltd. launched bendamustine hydrochloride ("bendamustine") in Singapore under the brand name Symbenda(R) as a treatment for low-grade non-Hodgkin's lymphoma and chronic lymphatic leukemia. more info >> |
|
|
|
